Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Myositis, Inclusion Body

• A Phase II/III Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
• Phase III Trial of Sirolimus in IBM
• A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)
• Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
• Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
• Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
• Study of Pioglitazone in Sporadic Inclusion Body Myositis
• Study of Arimoclomol in Inclusion Body Myositis (IBM)
• An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
• Natalizumab in Inclusion Body Myositis (IBM)
• Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
• Blood-flow Restricted Exercise in Inclusion Body Myositis
• Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
• Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
• Anakinra in Myositis
• Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
• Arimoclomol in Sporadic Inclusion Body Myositis
• Alemtuzumab to Treat Sporadic Inclusion Body Myositis
• Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies